Yankees Score with ...
Health Care: Drugs
Johnson & Johnson (JNJ: NYSE)
$86.82 -0.39 | -0.45%
05/24/13 - 04:01 PM ET
Company Cash Flow
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Cash Flow From Operating Activities | ||||
|---|---|---|---|---|
| Net Income (Loss) | 10.51B | 9.67B | 13.33B | 12.27B |
| Operating Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Extraordinary Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Receivables | -9.00M | -915.00M | -207.00M | 453.00M |
| (Increase) Decrease in Inventories | -1.00M | -715.00M | -196.00M | 95.00M |
| (Increase) Decrease In Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| (Decrease) Increase In Payables | 2.77B | 493.00M | 20.00M | -507.00M |
| (Decrease) Increase In Other Current Liabilities | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Other Working Capital | -4.73B | 2.79B | -487.00M | 1.24B |
| Other Non-Cash Items | 3.22B | 653.00M | 626.00M | 686.00M |
| Net Cash From Continuing Operations | 15.40B | 14.30B | 16.38B | 16.57B |
| Net Cash From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | 15.40B | 14.30B | 16.38B | 16.57B |
| Sale of Property, Plant & Equipment | 1.51B | 0.00 | 0.00 | 0.00 |
| Cash Used for Investing Activities | ||||
| Sale of Short-Term Investments | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchases of Property, Plant & Equipment | -2.93B | -2.89B | -2.38B | -2.36B |
| Acquisitions | -4.49B | -2.80B | -1.27B | -2.47B |
| Purchases of Short-Term Investments | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Cash from Investing Activities | 38.00M | 564.00M | 486.00M | 45.00M |
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | -4.51B | -4.61B | -7.85B | -7.60B |
| Issuance of Debt | 3.31B | 14.20B | 8.99B | 9.49B |
| Cash Used for Financing Activities | ||||
| Issuance of Capital Stock | 2.72B | 1.25B | 1.23B | 882.00M |
| Repayment of Long-Term Debt | -6.98B | -11.22B | -6.60B | -7.01B |
| Repurchase of Capital Stock | -12.92B | -2.52B | -2.80B | -2.13B |
| Payment of Cash Dividends | -6.61B | -6.16B | -5.80B | -5.33B |
| Other Financing Charges, Net | -83.00M | 0.00 | 0.00 | 0.00 |
| Net Cash From Financing Activities | -20.56B | -4.45B | -4.98B | -4.09B |
| Effect of Exchange Rate Changes | 45.00M | -47.00M | -6.00M | 161.00M |
| Net Change in Cash & Cash Equivalents | -9.63B | 5.19B | 3.54B | 5.04B |
Portfolios with JNJ
- Portfolio NameUser Type
- Userralphd5-12
- UserQuicksilver55
- UserDC
- ProGeorge Soros
- UserSlip's Portfolio
- ContributorStocks Fund Managers Love Q...
- ContributorGame of Thrones Portfolio
- UserCapt Jer
- ContributorRocket Stocks for the Week ...
- ContributorShort Squeezes for the Week...
Latest JNJ Headlines from TheStreet
- Dow Today: Johnson & Johnson (JNJ) Lower 05.24.13 | 01:05 pm
- Benefiting From the Rotation To Cyclicals
05.22.13 | 11:05 am - Dow Component Johnson & Johnson (JNJ) To Go Ex-dividend Tomorrow 05.22.13 | 11:05 am
- 5 Stocks Going Ex-Dividend Tomorrow: SMG, FMER, AIZ, KEY, JNJ 05.22.13 | 10:05 am
- Allocate Assets to Buy-Rated Dow Stocks 05.22.13 | 08:05 am
- Cramer's 'Mad Money' Recap: Think Dividends, Not Coupons 05.20.13 | 08:05 pm
- Cramer's 'Mad Money' Recap: Next Week's Game Plan 05.17.13 | 08:05 pm
- ASCO '13 Preview: Gilead's Big Cancer Debut 05.15.13 | 06:05 pm
- 5 Stocks Boosting The Drugs Industry Higher 05.15.13 | 01:05 pm
- Stryker's Stock Looks Pricey 05.15.13 | 07:05 am
Press Releases for JNJ
- Johnson & Johnson Pharmaceuticals Segment Poised To Continue Driving Growth With More Than 10 Potential New Product Filings By 2017 - PR Newswire 05.23.13 | 07:05 am
- Janssen And Johnson & Johnson To Provide Webcast Presentation Of Simeprevir Phase 3 Clinical Data Presented At The International Liver Congress Of The European Association For The Study Of The Liver (EASL) - PR Newswire 05.02.13 | 05:05 pm
- Johnson & Johnson Announces Dividend Increase Of 8.2% - PR Newswire 04.25.13 | 10:04 am
- Johnson & Johnson To Host Pharmaceuticals Business Review - PR Newswire 04.23.13 | 10:04 am
- Johnson & Johnson Announces Sale Of Elan American Depositary Shares To Elan - PR Newswire 04.18.13 | 09:04 am
- Johnson & Johnson To Webcast Annual Meeting Of Shareholders - PR Newswire 04.11.13 | 07:04 am
- Look And Feel Great This Spring, Despite Allergy Symptoms - PR Newswire 04.09.13 | 07:04 am
- Pharmaceutical Companies, Investor Coalition Develop Industry Standard-Setting Principles For Recoupment Policies Covering Major Compliance Failures - PR Newswire 04.04.13 | 08:04 am
- Johnson & Johnson To Host Analyst Conference Call On First-Quarter Results - PR Newswire 03.19.13 | 10:03 am
- Cordis Acquires Flexible Stenting Solutions, Inc. - Business Wire 03.12.13 | 09:03 am
Partner Headlines for JNJ
- Recession Is Coming - Seeking Alpha 05.24.13 | 08:05 am
- Alkermes Earnings Beat Estimates, But Outlook Unclear - Investor's Business Daily 05.23.13 | 06:05 pm
- Workday's Loss Narrows in 1Q - Analyst Blog - Zacks 05.23.13 | 03:05 pm
- Stock Market News for May 22, 2013 - Market News - Zacks 05.22.13 | 03:05 pm
- Johnson & Johnson (JNJ) Ex-Dividend Date Scheduled for May 23, 2013 - NASDAQ 05.22.13 | 01:05 pm
- Long-Term Biotech: 3 Names To Discover Now - Seeking Alpha 05.21.13 | 09:05 am
- Allergan, Inc. (AGN) Ex-Dividend Date Scheduled for May 21, 2013 - NASDAQ 05.20.13 | 01:05 pm
- Some Dividend ETFs Outperforming The S&P 500 - Investor's Business Daily 05.16.13 | 05:05 pm
- Nature's Sunshine Products, Inc. (NATR) Ex-Dividend Date Scheduled for May 16, 2013 - NASDAQ 05.15.13 | 01:05 pm
- Teva Pharmaceutical Industries Limited (TEVA) Ex-Dividend Date Scheduled for May 16, 2013 - NASDAQ 05.15.13 | 01:05 pm
